{"title":"别嘌呤醇两种片剂制剂的生物利用度和生物等效性","authors":"Santif Gen","doi":"10.35248/0975-0851.21.S2.001","DOIUrl":null,"url":null,"abstract":"Allopurinol is a compelling inhibitor of the catalyst xanthine oxidase, use for diminishing the blood centralizations of urate and, in this manner, to diminish the amount of rehashed attacks of gout. Allopurinol is used to oxipurinol, and hypouricaemic adequacy of allopurinol is expected in enormous part to this metabolite.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"82 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bioavailability and bioequivalence of allopurinol in two tablet formulations\",\"authors\":\"Santif Gen\",\"doi\":\"10.35248/0975-0851.21.S2.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Allopurinol is a compelling inhibitor of the catalyst xanthine oxidase, use for diminishing the blood centralizations of urate and, in this manner, to diminish the amount of rehashed attacks of gout. Allopurinol is used to oxipurinol, and hypouricaemic adequacy of allopurinol is expected in enormous part to this metabolite.\",\"PeriodicalId\":15184,\"journal\":{\"name\":\"Journal of Bioequivalence & Bioavailability\",\"volume\":\"82 1\",\"pages\":\"1-1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bioequivalence & Bioavailability\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/0975-0851.21.S2.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bioequivalence & Bioavailability","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/0975-0851.21.S2.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bioavailability and bioequivalence of allopurinol in two tablet formulations
Allopurinol is a compelling inhibitor of the catalyst xanthine oxidase, use for diminishing the blood centralizations of urate and, in this manner, to diminish the amount of rehashed attacks of gout. Allopurinol is used to oxipurinol, and hypouricaemic adequacy of allopurinol is expected in enormous part to this metabolite.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
